• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Abstract Clopidogrel is used in patients with coronary syndromes and at risk of thrombotic events or receiving percutaneous coronary intervention (PCI) for reducing heart attack and stroke. Here we present genotype and phenotype study of Iranian patients undergoing PCI treated with clopidogrel during a 6-month period of follow-up; common variants of CYP2C19, CYP3A5, CYP3A4, and ABCB1 genes were determined as well as the patients' cardiovascular outcomes to find out the effect of these variants individually and in combination. 388 individuals receiving PCI were enrolled in this study. Different pretreatment doses o...
Source: Cardiovascular Toxicology - May 18, 2018 Category: Cardiology Authors: Mahdieh N, Rabbani A, Firouzi A, Zahedmehr A, Hoseinimoghaddam M, Saeidi S, Sanati H, Basiri H, Noohi F, Rabbani B, Maleki M Tags: Cardiovasc Toxicol Source Type: research

Different Strategies in Simultaneous Coronary and Carotid Artery Revascularization - A Single Center Experience.
CONCLUSION: Synchronous PCI, CEA and CABG may be safe and effective in the management of patients with concomitant CAS and complicated multi-vessel CAD. The current data suggested that more studies and randomized controlled trials may be necessary to define whether this strategy is suitable for these patients. PMID: 31029069 [PubMed - in process]
Source: Archives of Iranian Medicine - February 28, 2019 Category: Middle East Health Authors: Zhang J, Dong Z, Liu P, Fan X, Chen J, Zheng X, Ma B, Ye Z Tags: Arch Iran Med Source Type: research

The Potential Effect of Intravenous Calcitriol on the Ischemia-Reperfusion Injury and ...
Conclusion: Administration of calcitriol in patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum inflammatory biomarkers in the serum (hs-CRP and hs-IL-6) and thus decrease the inflammatory reaction caused by PCI.
Source: Iranian Journal of Pharmaceutical Research - February 28, 2020 Category: Drugs & Pharmacology Source Type: research

Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention
CONCLUSION: The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.PMID:35537720 | DOI:10.15537/smj.2022.43.5.20220018
Source: Atherosclerosis - May 10, 2022 Category: Cardiology Authors: Seyed Mohammad H Adel Fateme Jorfi Hoda Mombeini Homeira Rashidi Saad Fazeli Source Type: research

Pages: 1  2